AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Oct 27, 2026, 6:00 AM ET Nautilus Biotechnology (NAUT) announced its participation in the ARPA-H-funded SEEDS consortium, expecting to receive up to $6 million to deploy its Voyager Platform to measure proteoforms in Alzheimer's disease and E… AI-generated summary · Source: company release
Nasdaq: $NAUTLife science tools · Single-molecule proteomicsTau proteoform study in Nature MethodsVoyager shipments planned for mid-2027Broadscale assay timeline deferred

NAUT Stock Hub: Nautilus Biotechnology News, Voyager and Proteoforms

Nautilus Biotechnology is building the Voyager platform, an instrument designed to count single, intact protein molecules and tell apart their variant forms, called proteoforms. In July 2026 it shifted resources toward targeted proteoform assays, now plans pre-orders in early 2027 and first instrument shipments in mid-2027, and deferred the timeline of its broadscale proteome assay. It had $114.3 million of cash and investments at September 30, 2026, no debt, and an unused $125.0 million at-the-market program. Third-quarter release · The realigned roadmap.

Last updated: November 19, 2026Financial period: quarter and nine months ended September 30, 2026Currency: U.S. dollars
Full research report · PDF
Nautilus Biotechnology, Inc. ($NAUT), research updated November 19, 2026
17 pages on Iterative Mapping and the Voyager platform, the tau proteoform study, the realigned roadmap and the broadscale delay, the Early Access Program, grants and ARPA-H funding, third-quarter accounts, cash and runway, the at-the-market program, options, insiders and holders. For personal use only: redistribution prohibited.
Get the report (PDF)
Next catalyst
Early 2027 · Voyager platform opens for pre-orders

The company expects to start its commercial launch in early 2027 by opening the Voyager platform for pre-orders, with instrument shipments beginning in mid-2027 together with the Tau Proteoforms assay, an AKT1 Proteoforms assay and a second oncology proteoforms assay. Form 10-Q, MD&A · Second-quarter release.

Earlier checkpoint: the AKT1 assay is expected to enter the Early Access Program in late 2026. Second-quarter release · See the dated calendar.

Nautilus Biotechnology NAUT daily stock chart
Daily chart $NAUT. Interactive chart with bull and bear scenarios on JC Just Charts →

NAUT stock at a glance

Chart analysis · JC
Technical chart analysis of $NAUT with bull and bear scenarios on JC Just Charts.
Cash and investments
$114.3M
September 30, 2026; $156.1M at December 31, 2025. Form 10-Q.
Net loss · third quarter
$(15.6)M
Versus $(13.6)M a year earlier; $(44.8)M in nine months. Form 10-Q.
Revenue · third quarter
$234K
$208K grant and $26K service revenue. Form 10-Q.
Debt
None
Operating lease liabilities of $26.7M. Form 10-Q, Note 8.
Shares outstanding
127.4M
October 22, 2026; 126.5M at December 31, 2025. Form 10-Q cover.
At-the-market program
$125.0M
New program of September 11, 2026; no shares sold. Form 8-K.

Where Nautilus Biotechnology stands now

Nautilus Biotechnology, Inc., with corporate headquarters in Seattle, Washington and research and development headquarters in San Carlos, California, is a development stage life sciences company. It was incorporated in 2016 and became public through a business combination in June 2021 that brought about $345.5 million of gross proceeds. It is developing Iterative Mapping, a method for counting single, intact protein molecules at scale, and the Voyager platform that implements it. Third-quarter release · Form 10-Q

The company recorded its first revenue in the second quarter of 2026: grant revenue from The Michael J. Fox Foundation (MJFF) for an alpha-synuclein proteoform assay and service revenue from its Iterative Mapping Early Access Program, which launched in January 2026 with a Tau Proteoforms assay. Third-quarter revenue was $234 thousand. Second-quarter release · Form 10-Q

In July the company realigned its roadmap. It moved resources toward targeted proteoform assays, set an early 2027 opening of Voyager pre-orders with shipments from mid-2027, and said that testing had shown its broadscale assay would not reach target specifications for a 2027 kit; it plans to report a commercial timeline for that assay later. In October it said the proteoform pipeline is advancing toward twenty assays planned through mid-2028. Second-quarter release · Third-quarter release

The science gained visibility in 2026 with a peer-reviewed paper in Nature Methods on tau proteoforms, and after the quarter the company announced participation in SEEDS, a four-year research consortium funded by the Advanced Research Projects Agency for Health (ARPA-H), from which it expects up to $6 million. Third-quarter release · Nat Methods, 2026

The central question. Can Nautilus turn a published, high-precision tau assay into an instrument business, shipping from mid-2027 with three assays and building to twenty by mid-2028, before its $114.3 million of cash and investments runs low, and how much of the $125.0 million at-the-market program will it need along the way? Form 10-Q · Form 8-K

▲ The constructive case

A peer-reviewed method in a major journal, a working service business with paying early access customers, grant and government funding, first oncology assay data matching tau performance, no debt, operating expenses kept below 2025 levels over nine months, and a dated launch plan.

▼ The cautious case

No instrument on sale yet, revenue of $424 thousand in nine months, the broadscale assay that defined the original vision now without a timeline, cash down $41.8 million in nine months, a liquidity statement that covers at least twelve months, an unused $125.0 million at-the-market program, options equal to 14.8% of shares, and two large holders that cut stakes below 5%.

Latest Nautilus Biotechnology news

Oct 27, 2026

Third-quarter results: revenue of $0.2 million, net loss of $15.6 million, cash and investments of $114.3 million

Nautilus reported third-quarter 2026 revenue of $0.2 million, primarily grant revenue under the Michael J. Fox Foundation award and service revenue from the Iterative Mapping Early Access Program. Operating expenses were $16.9 million, up $1.5 million (10%) from $15.5 million a year earlier on higher laboratory and professional services and higher salaries and related benefits, partly offset by lower facilities expenses. Net loss was $15.6 million (third quarter of 2025: $13.6 million). Cash, cash equivalents and investments were $114.3 million at September 30, 2026, against $129.2 million at June 30. The company said it advanced the proteoform assay pipeline needed for the twenty assays planned through mid-2028, shared first oncology proteoform assay data, including AKT1, at World HUPO 2026, and reaffirmed planned instrument availability in the middle of 2027. After quarter end it announced participation in SEEDS, a four-year, multi-center consortium funded by ARPA-H, under which it expects to receive up to $6 million; the company cautioned that the SEEDS funding may be reduced, delayed or terminated.

Oct 15, 2026

Third-quarter results set for October 27

Nautilus will report third-quarter 2026 results before the market opens on Tuesday, October 27, 2026, followed by a webcast conference call at 8:30 a.m. Eastern (5:30 a.m. Pacific) on the Investors section of its website.

Sep 18, 2026

ATM prospectus filed, shelf effective

The 424B5 covers sales of up to $125 million through TD Cowen; the S-3 became effective the same day. Capacity, not cash raised.

Sep 11, 2026

TD Cowen sales agreement and $300 million shelf

8-K on the at-the-market agreement, commission up to 3.0%; the ATM sits inside the shelf, so the two amounts are not cumulative.

Sep 11, 2026

a16z funds below 5%

The 13D/A reports open-market sales from August 31 to September 9 and a remaining 6,263,235 shares, 4.9%. Not a complete exit.

Sep 4, 2026

Tau proteoforms in Nature Methods

130 tau proteoform groups quantified, median CV below 5.5%; AKT1 set for early access in late 2026, about 20 assays targeted by mid-2028.

NAUT stock catalysts: the dated calendar

  • January 2026 — Early Access Program launches with the Tau Proteoforms assay. Completed · Form 10-Q, MD&A
  • February 26, 2026 — Fourth-quarter results and annual report for 2025. Completed · Form 10-K
  • March 2–4, 2026 — Annual option grants to officers; the chief executive buys 25,000 shares. Completed · Form 4 · Form 4
  • June 2, 2026 — Andreessen Horowitz funds sell 5,000,000 shares. Completed · Form 4
  • June 17, 2026 — Annual meeting re-elects two Class II directors. Completed · Form 8-K
  • July 28, 2026 — Second-quarter results and realigned roadmap; broadscale timeline deferred. Completed · release
  • September 11, 2026 — New $125.0 million at-the-market agreement replaces the 2024 program. Completed · Form 8-K
  • September 18, 2026 — Shelf registration effective; prospectus supplement filed. Completed · 424B5
  • Third quarter of 2026 — Tau proteoform paper in Nature Methods; AKT1 data at World HUPO 2026. Completed · release
  • October 27, 2026 — Third-quarter results; ARPA-H SEEDS participation announced. Completed · release
  • Late 2026 — AKT1 assay enters the Early Access Program. Company plan · release
  • Early 2027 — Voyager opens for pre-orders. Company plan · Form 10-Q
  • Mid-2027 — First instrument shipments; Tau, AKT1 and a second oncology kit generally available. Company plan · release
  • Late 2027 — Third oncology kit and further proteoform kits. Company plan · release
  • Mid-2028 — Twenty proteoform assays planned. Company plan · release
  • Date to be set — Commercial timeline for the broadscale assay. Pending · release

The product roadmap in one table

ProductStatus in 2026Planned availability
Voyager instrumentNot commercially availablePre-orders early 2027; shipments mid-2027
Tau Proteoforms assayOffered as a service in the Early Access Program since January 2026Consumable kits mid-2027
AKT1 Proteoforms assay (oncology)Development data shown at World HUPO 2026Early Access late 2026; kits mid-2027
Second oncology proteoforms assayIn developmentKits mid-2027
Third oncology assay and more proteoformsIn developmentKits late 2027; twenty assays through mid-2028
Broadscale proteome assayPerformance short of target specificationsTimeline to be reported later

Source: second-quarter release · third-quarter release · Form 10-Q, MD&A. The company also plans to extend the platform to more sample types, including blood, beyond the cells and tissues already enabled, and to lower sample input requirements.

Nautilus Biotechnology deep dive: the full analysis

The chapters below follow one thread: whether Nautilus can move from a published single-molecule method and a small service business to selling instruments and assay kits from mid-2027, while its cash, now $114.3 million, carries it through launch and its at-the-market program remains a backstop rather than a necessity. They cover three scenarios and what would falsify this analysis, the business, what peer-reviewed research says, Iterative Mapping and the tau study, the realigned roadmap, early access, grants and ARPA-H funding, third-quarter accounts, cash and runway, the at-the-market program and dilution, insiders and holders, and an overall assessment. The Merlintrader Research Library collects our dated biotech stock research reports.

01 Three scenarios for NAUT stock

The scenarios below describe how the facts in the filings could develop over the next twelve to eighteen months, with the AKT1 early access launch, the opening of pre-orders, the first shipments and the use of the at-the-market program as the main decision points. They carry no probabilities.

Constructive

AKT1 enters the Early Access Program on schedule, pre-orders open in early 2027 with orders from early access customers, and the first instruments ship in mid-2027 with three assay kits. SEEDS and MJFF funding cover part of the assay work, and quarterly cash use stays near the 2026 pace, so that the company reaches shipments with a large share of its current cash and little use of the at-the-market program. Form 10-Q, MD&A · Third-quarter release · Second-quarter release, July 28, 2026

Base

The launch happens broadly on time but early instrument sales are few and slow while the company adds sales and support staff. Selling, general and administrative expenses rise as the company has said they will, and it sells shares under the at-the-market program during 2027 to extend its runway. Form 10-Q, MD&A and liquidity section · Form 8-K

Cautious

Instrument or kit validation takes longer, shipments slip beyond mid-2027, and early access demand does not convert into orders. With no broadscale timeline and cash falling, the company leans on the at-the-market program or other equity at a difficult moment, increasing the share count materially. Form 10-Q, risk factors · Second-quarter release

The constructive scenario’s pace is a Merlintrader calculation: nine-month operating cash use of $40,107 thousand divided by three is $13,369 thousand per quarter; at that pace, $114,343 thousand of cash and investments would cover about 8.6 quarters. The company itself commits only to at least twelve months and expects costs to rise. Form 10-Q, cash flow statement and liquidity section

What would falsify this analysis

The analysis rests on four assumptions; the filing or release that tests each one is cited beside it.

  • The launch dates hold. The analysis treats early 2027 pre-orders and mid-2027 shipments as the company’s working plan. A disclosure moving either date would change the outlook. Form 10-Q, MD&A
  • Assay performance repeats. The company says AKT1 matched the tau performance profile. Oncology assays that fail to reach tau-like precision would undermine the plan of twenty assays by mid-2028. Third-quarter release
  • The realignment is cost-neutral. The company says the shift is funded by reallocation rather than incremental spend. A sharp rise in research or commercial spending would shorten the runway. Second-quarter release
  • Customers want proteoforms. The analysis assumes early access interest reflects real demand. Service revenue that stays near current levels into 2027 would suggest otherwise. Form 10-Q, income statement

02 What Nautilus does

Since its incorporation in 2016 Nautilus has devoted substantially all of its resources to research and development of its proteomics platform. Before the 2021 business combination it raised $108.4 million net from private placements of convertible preferred stock; the combination and an accompanying private placement brought about $345.5 million of gross proceeds, less about $18.2 million of transaction costs and fees. Form 10-Q, notes and liquidity section

The platform

Iterative Mapping is designed to characterize proteins by repeatedly probing individual, intact protein molecules and aggregating the results across billions of measurements into digital protein counts. The Voyager platform combines nanofabricated protein arrays, affinity reagent probing, optics and fluidics, and machine learning-based analysis into a workflow of instrument, consumables and software. Form 10-Q, MD&A

Two product lines

The company describes two applications. Targeted proteoform analysis measures the different forms of one protein, such as tau with its many phosphorylation patterns. Broadscale analysis aims to measure a large part of the proteome at once and was the original long-term vision; its timeline is now open. Form 10-Q, MD&A · Second-quarter release

How it plans to sell

Commercialization proceeds in phases: research collaborations with biopharmaceutical companies and academic institutions on pre-commercial versions, then a land-and-expand approach that starts customers on one application and adds more over time. The company intends to sell directly in the United States and through direct and distributor channels abroad. It made its first sales hires in the first half of 2026 and had three commercial team members, including a vice president of global sales, by the second quarter. Form 10-Q, MD&A · Second-quarter release

Manufacturing in volume will require internal capacity, contract partners or both, and the platform depends on reagents and antibodies that the company expects to be more difficult and more expensive to procure than standard ones. Form 10-Q, MD&A

03 What the research literature says

Peer-reviewed literature places Nautilus’s technology in context. The studies below are linked to their journal records; the first is the company’s own study.

The tau proteoform study

The company’s paper in Nature Methods in 2026 introduced Iterative Mapping of proteoforms, which interrogates millions to billions of single protein molecules with fluorescently labeled antibodies. Applied to tau with 12 site-specific antibodies, the assay detected proteoforms at 0.1% abundance, showed a median coefficient of variation below 5.5% and a dynamic range above three orders of magnitude. In organoids, mouse brains and human Alzheimer’s disease samples it found 130 distinct tau proteoform groups with up to six phosphorylation events, distributed in a non-random way that suggests ordered modification. Nat Methods, 2026

Why proteoforms matter

The Human Proteoform Project, proposed in Science Advances in 2021, argued that proteins exist in many proteoforms produced by genetic variation, splicing and post-translational modifications, that this knowledge is largely missing, and that better technologies are needed to define the human proteome at that level. Sci Adv, 2021

A 2025 review in Clinical Chemistry notes that most clinical assays measure protein quantity and miss proteoform information, and gives phosphorylated tau proteoforms in Alzheimer’s disease as one of the modified proteoforms that have already moved from discovery to clinical use. Clin Chem, 2025

A 2026 review in Expert Review of Proteomics describes blood-based tau proteoforms as emerging scalable biomarkers of Alzheimer’s pathology, citing the first FDA-cleared plasma assay in May 2025 and expecting high-plex mass spectrometry in referral centers alongside automated immunoassays in primary care. For Nautilus this shows a real clinical interest in tau proteoforms, and also competition from established methods; the company’s plan to enable blood samples is directly relevant. Expert Rev Proteomics, 2026

Where Voyager sits among proteomics platforms

A 2026 review in Biochimica et Biophysica Acta – Proteins and Proteomics compares mass spectrometry, SomaScan, the Olink Proximity Extension Assay and Nautilus Voyager. It describes mass spectrometry as the cornerstone for unbiased identification of proteins and proteoforms, and the affinity platforms as complementary rather than interchangeable, since each reads different molecular features; Voyager infers intact-protein identity from cumulative binding patterns. Biochim Biophys Acta Proteins Proteom, 2026

A 2026 comparison in Genome Biology of three high-throughput plasma platforms in a multi-ethnic Asian cohort found only 1,740 proteins in common out of 12,825 quantified, with modest correlations between platforms. Such results show both the opening for new methods and the difficulty any platform faces in proving that its measurements agree with, or improve on, existing ones. Genome Biol, 2026

Single-molecule protein analysis as a research field

A 2020 review in Science Advances set out the case for alternatives to mass spectrometry: proteomics has lagged behind genomics, and mass spectrometry classifies rather than truly sequences a protein and typically needs about a billion copies of it. The authors surveyed single-molecule alternatives that offer better sensitivity and promise to scale. Science Advances, 2020

A 2022 review in the Annual Review of Biophysics groups single-molecule protein sequencing methods into three families: sequencing by degradation, such as mass spectrometry or fluorosequencing; sequencing by transit, such as nanopores or quantum tunneling; and sequencing by affinity, by analogy with DNA hybridization. It describes the field as nascent, with approaches ranging from experimentally well supported to merely speculative. Annual Review of Biophysics, 2022 Voyager, which reads repeated antibody binding to single intact molecules, is closest to the affinity family, although it maps proteins rather than sequencing them amino acid by amino acid.

A 2026 review in the Annual Review of Analytical Chemistry notes that proteins cannot be amplified, have complex chemical structures and exist as a vast range of proteoforms. It finds that while many new strategies are still at an early stage, a few, including fluorosequencing, single-molecule sequencing, digital proteomics mapping and nanopore-based protein sequencing, have reached or are nearing commercial use. Annual Review of Analytical Chemistry, 2026

A 2025 perspective in Nature Biotechnology predicts that, more likely than not, nanopores will become able to identify full-length proteins one molecule at a time with single-amino-acid resolution, which would help measure the heterogeneity of post-translational modifications, quantify low-abundance proteins and characterize protein splicing. Nature Biotechnology, 2025 These are the same applications that Nautilus targets with proteoform mapping, so the literature points to a field in which several single-molecule approaches are converging on the same questions, not only to competition from mass spectrometry and affinity panels.

Plasma: the sample-preparation problem

Blood is the sample the company plans to enable, and the plasma literature shows how sensitive results are to preparation. A 2025 study in EMBO Molecular Medicine compared five plasma workflows, including three bead-based enrichment methods, using spiked-in low-abundance proteins and defined cellular contaminants. Bead-based methods improved detection of low-abundance proteins but could be highly susceptible to bias from contamination from platelets and peripheral blood mononuclear cells, which can inflate results by thousands of proteins, while a perchloric acid workflow resisted contamination; centrifugation, anticoagulant and buffer choices changed the contamination profile, and optimized handling reduced the bias. EMBO Molecular Medicine, 2025 Any new plasma platform, including a single-molecule one, will need to show that its protein counts are robust to these pre-analytical factors.

04 Iterative Mapping and the tau study

Tau, the microtubule-binding protein broadly linked to the onset and progression of Alzheimer’s disease, is the first application. The Tau Proteoforms assay has been offered since January 2026 as a service: the company analyzes customer samples in its own facility and shares data through a cloud platform. Form 10-Q, MD&A

The Nature Methods paper gives that service a peer-reviewed basis. Its reported precision, a median coefficient of variation below 5.5%, and its ability to separate closely related proteoform groups are the properties that matter to research customers comparing samples over time. Nat Methods, 2026 · Third-quarter release

The company’s next step is to show the same performance on other proteins. At World HUPO 2026 it presented first development data on oncology assays, including AKT1, a kinase that acts as a control hub for cell growth and survival signals and is active in many cancers, and said the results show a performance profile matching tau. Third-quarter release · Form 10-Q, MD&A

MJFF funding supports an alpha-synuclein proteoform assay, extending the neuroscience work beyond tau. Second-quarter release

The study and the early data are company-generated. Independent replication by customers, and publications from early access users, are what the company itself plans to use to drive demand. Form 10-Q, MD&A

05 The realigned roadmap and the broadscale delay

On July 28, 2026, citing customer interest in proteoform targets, the company said it was significantly shifting resources across the company and putting a new roadmap in place to accelerate proteoform applications. The chief executive said the shift is funded through reallocation rather than incremental spend and does not affect the company’s broader financial assumptions. Second-quarter release

The new plan opens Voyager for pre-orders in early 2027 and ships instruments from mid-2027 together with consumable kits for Tau, AKT1 and a second oncology proteoform, followed by a third oncology assay and further kits in late 2027. The company also plans lower sample input, additional sample types and greater proteoform depth. Second-quarter release

The broadscale assay moved the other way. In the second quarter the company completed testing and found that assay configuration changes do not sufficiently improve probe performance to support a 2027 general availability of a broadscale kit at target specifications. It has identified improvement areas, begun development work and plans to report a commercial timeline later. Second-quarter release

In October the company said its proteoform pipeline is advancing toward twenty assays planned through mid-2028, and that its expansion initiative is on track. It does not expect early access activities to produce material revenue; the commercial model rests on later sales of instruments and reagents. Third-quarter release · Form 10-Q, MD&A

The realignment narrows the near-term market from the whole proteome to targeted proteoform research, which is a smaller but more concrete opportunity, and it postpones the broadscale product that underpinned the company’s original pitch. Second-quarter release

06 Early Access, grants and ARPA-H funding

Revenue began in the second quarter of 2026 from two sources: grant revenue from MJFF, recognized as qualifying costs are incurred, and service revenue from Early Access Program customers, recognized when proteomic data are generated and delivered. Form 10-Q, revenue recognition note

In the third quarter grant revenue was $208 thousand and service revenue $26 thousand, against a cost of service revenue of $24 thousand; over nine months grant revenue was $388 thousand and service revenue $36 thousand. Form 10-Q, statements of operations

After the quarter, the company announced participation in SEEDS, a four-year, multi-center research consortium funded by ARPA-H, expecting to receive up to $6 million to deploy Voyager to measure proteoforms driving Alzheimer’s disease and cancer. It cautions that the funding may be reduced, delayed or terminated, and its risk factors note that U.S. government funding gives the government certain rights in resulting inventions. Third-quarter release · Form 10-Q, risk factors

The company has begun capitalizing inventory costs and recording accounts receivable in connection with early access and commercial activities, small signs of a shift toward operations. Form 10-Q, notes

07 Third-quarter accounts

In thousands of dollarsQ3 2026Q3 20259M 20269M 2025
Total revenue234—424—
Cost of service revenue(24)—(39)—
Research and development(10,176)(9,605)(29,496)(31,535)
Selling, general and administrative(6,771)(5,867)(19,513)(19,878)
Total operating expenses(16,947)(15,472)(49,009)(51,413)
Interest income1,1731,9033,9226,214
Other expense(72)(5)(100)(21)
Net loss(15,636)(13,574)(44,802)(45,220)

Source: Form 10-Q, statements of operations. Merlintrader calculation for the quarter: $234 − $24 − $16,947 + $1,173 − $72 = −$15,636 thousand. The net loss per share was $0.12, against $0.11 a year earlier.

Research and development rose by $0.6 million, or 6%, to $10.2 million: laboratory and professional services rose $0.7 million and salaries $0.3 million, offset by $0.2 million less depreciation and $0.2 million less facilities expense. Selling, general and administrative expenses rose by $0.9 million, or 15%, to $6.8 million: professional services, mainly legal and marketing, rose $0.6 million and salaries $0.4 million, the latter because incentive pay was reduced in the prior-year period, offset by $0.1 million less facilities expense. Form 10-Q, MD&A

Interest income fell by $0.7 million because of a lower cash and investment balance and lower yields. Over nine months, operating expenses were $2.4 million below 2025, reflecting a workforce reduction in the first quarter of 2025, and stock-based compensation fell to $3.8 million from $5.4 million. The company expects both research and development and selling, general and administrative expenses to increase as it moves toward launch. Form 10-Q, MD&A

08 Cash and runway

Cash and cash equivalents were $10.5 million at September 30, 2026, short-term investments $76.1 million and long-term investments $27.8 million, for $114.3 million in total. Merlintrader calculation: $10,467 + $76,109 + $27,767 = $114,343 thousand, against $12,388 + $91,018 + $52,739 = $156,145 thousand at December 31, 2025, a decline of $41,802 thousand. Form 10-Q, balance sheet

Cash flow, nine months (in thousands)20262025
Net cash used in operating activities(40,107)(38,321)
Net cash provided by investing activities36,69334,437
Net cash provided by financing activities1,375113
Net decrease in cash, equivalents and restricted cash(2,039)(3,771)

Source: Form 10-Q, statements of cash flows. Merlintrader calculation: −$40,107 + $36,693 + $1,375 = −$2,039 thousand. Investing inflows reflect $76,596 thousand of maturities less $37,494 thousand of purchases and $2,409 thousand of equipment; financing came from option exercises of $1,233 thousand and the employee stock purchase plan of $142 thousand.

The company believes its cash, cash equivalents and investments will fund its operating expenses and capital expenditures for at least the next twelve months, and states that it will need to seek additional equity or debt financing to fund future operations, possibly on unfavorable terms. Form 10-Q, notes and liquidity section

Obligations

The company has no debt. Operating lease liabilities were $26.7 million at September 30, 2026, against $33.1 million of future minimum payments through 2031 and beyond, for offices and laboratories in Seattle and San Carlos; the San Diego lease expired in 2026. It holds $0.9 million of cash-collateralized letters of credit for the San Carlos leases. Form 10-Q, Note 8

09 The at-the-market program and dilution

On September 11, 2026 the company signed a new sales agreement with TD Securities (USA) LLC, as TD Cowen, for an at-the-market program of up to $125.0 million, with agent compensation of up to 3.0% of gross proceeds, and terminated the February 2024 agreement of the same size, under which no shares had been sold. The new shelf registration became effective on September 18, 2026. No shares were sold under either agreement in the first nine months of 2026, and no securities had been sold under the new shelf by the filing of the Form 10-Q. Form 8-K · Prospectus supplement · Form 10-Q, liquidity section

Shares outstanding rose from 126,469,610 at December 31, 2025 to 127,328,617 at September 30, 2026, an increase of 859,007 or 0.7%, mainly from 774,221 option exercises, and stood at 127,372,425 on October 22, 2026. Form 10-Q, cover and Note 5

At September 30, 2026, 18,816,169 stock options were outstanding, of which 12,304,163 were vested and exercisable, and a further 33,345,527 shares were available for grant under the 2021 Equity Incentive Plan. Merlintrader calculation: 18,816,169 ÷ 127,328,617 = 14.8% of shares outstanding. During the nine months 3,850,500 options were granted and 1,530,980 forfeited. Form 10-Q, Notes 5 and 7

The at-the-market program is capacity, not cash received. Its size relative to the company’s cash means that heavy use would raise the share count substantially; the company names sales under the agreement among its intended funding sources. Form 10-Q, liquidity section

10 Insiders, holders and governance

Insider holdings

Two insiders hold the largest stakes. Sujal Patel, chief executive officer, president and director, reported beneficial ownership of 21,249,965 shares, 16.3% of the class, and Parag Mallick, chief scientist and director, 22,557,411 shares, 17.6%, in Schedule 13D amendments for events on March 2, 2026. Patel bought 25,000 shares in the open market on March 4, 2026 (code P). 13D/A: Patel · 13D/A: Mallick · Form 4

Option awards

On March 2, 2026 the board granted annual options (code A): 650,000 to Patel, 280,000 to Mallick and 160,000 each to the chief financial officer, Anna Mowry, and four other officers. On June 18, 2026 five directors received 45,000 options each. Form 4: Patel · Mallick · Mowry · director award example

Large holders reducing

HolderFilingEvent dateSharesPercent of class
Andreessen Horowitz funds13D/AJune 2, 202612,653,9179.9%
Andreessen Horowitz funds13D/AJune 26, 20269,063,0547.1%
Andreessen Horowitz funds13D/AAugust 26, 20267,684,9326.0%
Andreessen Horowitz funds13D/ASeptember 9, 20266,263,2354.9%
Perceptive Advisors13D/AJune 30, 202611,634,2119.1%
Perceptive Advisors13D/AOctober 5, 20264,944,5123.9%

Both holders fell below 5%, which marks an exit from the reporting threshold. The Andreessen Horowitz funds reported a sale of 5,000,000 shares on June 2, 2026 (code S) on Form 4. Merlintrader calculation of the Andreessen Horowitz reduction over the four amendments: 12,653,917 − 6,263,235 = 6,390,682 shares. Form 4 · 13D/A, September 2026 · 13D/A, October 2026

Governance

At the annual meeting on June 17, 2026, stockholders re-elected Parag Mallick and Farzad Nazem as Class II directors until 2029, ratified PricewaterhouseCoopers LLP as auditor for 2026 and voted on executive pay on an advisory basis; 85,002,191 of 127,078,855 shares outstanding at the April 20, 2026 record date were represented. Form 8-K

11 Competition, intellectual property and supply

A crowded field of large suppliers

The company states that it faces significant competition from technology and diagnostic companies that supply proteomics customers. It names Thermo Fisher Scientific, including Olink, Bruker, Agilent Technologies, Danaher through SCIEX, Becton, Dickinson and Company, Quanterix, and Illumina through the former SomaLogic business acquired from Standard BioTools, and adds a number of emerging companies developing proteomic products. Form 10-Q, risk factors

These competitors sell established mass spectrometry instruments, affinity panels and immunoassays to the same laboratories that Nautilus targets, and they already own installed bases, service networks and validated workflows. Nautilus’s argument is that single-molecule counting of intact proteins reveals proteoform detail that bulk methods cannot resolve; the literature summarized in chapter 03 supports the scientific interest in proteoforms while also describing existing tools, including mass spectrometry and plasma immunoassays for tau, that reach some of the same questions by other routes. Biochim Biophys Acta Proteins Proteom, 2026 · Expert Rev Proteomics, 2026

Product cycles and technical specifications

The company’s risk factors stress that life sciences products have long and complex development cycles that can require new scientific advances, external suppliers and service providers, and that products that miss technical specifications or schedules can be harmed. The broadscale result of the second quarter is an example of that risk materializing: assay configuration changes did not lift probe performance to the level needed for a 2027 kit. Form 10-Q, risk factors · Second-quarter release

Even after launch, the company says its ability to win and keep customers will depend on improving the platform and introducing new products on time, at competitive prices and with adequate quality testing, integration with existing technologies and freedom from intellectual property encumbrance. Form 10-Q, risk factors

Patents

The company describes the patent position of life sciences technology companies as highly uncertain and notes that court decisions have increased the probability that claims reciting natural phenomena or abstract ideas are held ineligible. It may not be aware of all third-party rights relevant to its products, since patent applications are typically published about 18 months after filing. Government-funded work, such as SEEDS, gives the government certain rights in resulting inventions. Form 10-Q, risk factors

Supply chain

The platform depends on specialized materials. The company has experienced supply disruptions in the past, including closures at certain chip manufacturers that extended lead times for some chips and reduced the availability of certain reagents; some of these have been resolved and the company continues to monitor its supply chain. Building volume manufacturing, internally or through partners, is still ahead of it. Form 10-Q, MD&A

What this means for the launch

The competitive setting raises the bar for the first shipments in mid-2027. Customers will compare Voyager’s cost, throughput, sample requirements and data quality with tools they already use, and early access results and publications are the evidence the company plans to bring to that comparison. The planned extension to blood samples and lower input amounts addresses two practical requirements of many research laboratories. Form 10-Q, MD&A · Second-quarter release

12 Assessment

Nautilus has turned an ambitious idea into a published method and a small paid service, and has set dated commercial milestones for 2027. Its finances are simple: no debt, $114.3 million of cash and investments, quarterly cash use of about $13 million over the first nine months, and a large unused at-the-market program. Form 10-Q · Form 8-K

The weaknesses are equally clear. The company has no instrument on sale, revenue under half a million dollars in nine months, and a broadscale product whose timeline it has withdrawn. Two large investors, the Andreessen Horowitz funds and Perceptive Advisors, have reduced their holdings below 5%, and the combined stake of the chief executive and the chief scientist, about a third of the shares, concentrates control. Second-quarter release · 13D/A · 13D/A

The next twelve months come down to three checks: AKT1 entering early access in late 2026, pre-orders opening in early 2027, and first shipments in mid-2027. Each will be reported in a company release, and each will show whether demand for proteoforms reaches beyond early access customers. Form 10-Q, MD&A · Third-quarter release · Second-quarter release, July 28, 2026

Merlintrader Health Score · $NAUT

2.60out of 5
Balance sheet and cash generation · 30%3.0

$114.3 million of cash and investments and no debt, but a decline of $41.8 million in nine months and a liquidity statement covering at least twelve months.

Catalyst · 30%2.5

Pre-orders in early 2027 and shipments in mid-2027 are dated, while the broadscale assay has no timeline.

Dilution and capital allocation · 20%2.0

Share count up only 0.7% in nine months, but a $125.0 million at-the-market program and options equal to 14.8% of shares.

Liquidity · 10%3.0

Nasdaq listing with about 127.4 million shares. The company received a minimum bid price notice in May 2025 and regained compliance on November 3, 2025. The Form 10-Q warns that a closing bid below $1.00 for 30 consecutive business days could trigger another notice; the chief executive and chief scientist hold about a third and two large holders fell below 5%.

Execution · 10%2.5

A peer-reviewed method, first revenue and oncology assay data, against a deferred broadscale product.

Assessed on November 19, 2026, on the Form 10-Q for the quarter ended September 30, 2026 and the filings and releases through November 19, 2026. Weighted calculation: 3.0×30% + 2.5×30% + 2.0×20% + 3.0×10% + 2.5×10% = 0.90 + 0.75 + 0.40 + 0.30 + 0.25 = 2.60. The previous published score was 2.60. The score describes financial and operational robustness over twelve to eighteen months and carries no rating, price target or trading indication.

Red flags

  • The Voyager platform is not commercially available; first shipments are planned for mid-2027.
  • The broadscale assay did not reach target specifications for 2027 and has no commercial timeline.
  • Revenue was $424 thousand in nine months, against a net loss of $44.8 million.
  • Cash and investments fell by $41.8 million in nine months, to $114.3 million.
  • A $125.0 million at-the-market program is in place and the company names it as a funding source.
  • Options outstanding equal 14.8% of shares.
  • The Form 10-Q warns that a closing bid price below $1.00 for 30 consecutive business days could again put the Nasdaq listing at risk; Nautilus received such a notice in May 2025 and regained compliance in November 2025.
  • Andreessen Horowitz funds and Perceptive Advisors reduced their stakes below 5%.
  • SEEDS funding of up to $6 million may be reduced, delayed or terminated.

NAUT Stock FAQ: Nautilus Biotechnology Questions Answered

When will Nautilus launch the Voyager platform?

The company expects to open Voyager for pre-orders in early 2027 and to begin instrument shipments in mid-2027, together with Tau, AKT1 and a second oncology proteoform assay kit. Form 10-Q, MD&A · Second-quarter release.

Is NAUT making revenue yet?

Yes, a small amount since the second quarter of 2026: $234 thousand in the third quarter, of which $208 thousand was grant revenue from MJFF and $26 thousand service revenue from the Early Access Program; $424 thousand in nine months. The company does not expect early access to produce material revenue. Form 10-Q.

How much cash does Nautilus Biotechnology have?

$114.3 million of cash, cash equivalents and investments at September 30, 2026, with no debt. Operating cash use was $40.1 million in nine months, and the company expects its resources to last at least twelve months. Form 10-Q.

Has NAUT used its ATM stock offering?

No. No shares were sold under the February 2024 program, which was terminated, or under the new $125.0 million program signed with TD Cowen on September 11, 2026, through the filing of the third-quarter Form 10-Q. Form 8-K · Form 10-Q.

When are the next NAUT earnings?

Third-quarter results were released on October 27, 2026. The date for fourth-quarter and full-year 2026 results has not been announced; the 2025 results and annual report came on February 26, 2026. Release · Form 10-K.

What does Nautilus Biotechnology do?

It develops Iterative Mapping, a method for counting single, intact protein molecules, and the Voyager platform of instrument, consumables and software that implements it, starting with targeted proteoform assays such as tau. Form 10-Q.

What did Nautilus’s tau study show?

In Nature Methods in 2026, the company’s tau assay with 12 site-specific antibodies detected proteoforms at 0.1% abundance with a median coefficient of variation below 5.5%, and found 130 tau proteoform groups in organoids, mouse brains and human Alzheimer’s disease samples. Nat Methods, 2026.

What is Nautilus’s ARPA-H SEEDS funding?

On October 27, 2026 the company announced participation in SEEDS, a four-year research consortium funded by ARPA-H, expecting up to $6 million to use Voyager to measure proteoforms driving Alzheimer’s disease and cancer. The funding may be reduced, delayed or terminated. Third-quarter release.

Sources

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $NAUT or any other security.

Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, court records and market-data providers, and are stated with their reference dates. Data can change without notice. Readers should verify every figure against the primary source before acting on it.

Life science tools companies at the development stage carry technical, commercial and financing risk. Platforms can miss performance targets, launches can slip, customers may adopt new methods slowly or not at all, and companies without product revenue depend on capital markets. This company has no commercially available instrument, reported a net loss of $44.8 million for the nine months ended September 30, 2026, plans first instrument shipments for the middle of 2027, has deferred the timeline of its broadscale assay, and has a $125.0 million at-the-market program and stock options that can increase the share count. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.